IL-32 as a potential biomarker and therapeutic target in cardiovascular disease
Cardiovascular diseases remain a leading cause of death worldwide, driven by complex pathological mechanisms involving various cytokines and inflammatory responses. IL-32, a recently discovered cytokine, has emerged as a key player in the pathogenesis of cardiovascular diseases, including atherosclerosis, myocardial infarction, and heart failure. This review summarizes the biological characteristics of IL-32 and its role in cardiovascular diseases, explores its involvement in inflammatory responses and other pathological processes, and evaluates its potential as both a biomarker and a therapeutic target. Collectively, this review aims to provide new insights for the prevention and treatment of cardiovascular diseases.
Authors
- Qingwei Ji
- Jing Ye
- Lingyue Qiu
- Ling Liu
Institutions
- Wuhan University (CN)
- The People's Hospital of Guangxi Zhuang Autonomous Region (CN)
- Renmin Hospital of Wuhan University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-04-22
- DOI
- https://doi.org/10.3389/fimmu.2026.1755759
- Primary Topic
- Cytokine Signaling Pathways and Interactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China